Tatu Rimpilainen

Tatu Rimpilainen

Auto-generated profile, based on publicly available information

Tatu Rimpilainen

Faculty of Engineering and Natural Sciences, Tampere University, Korkeakoulunkatu 8, 33101, Tampere, Finland

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
TRTatu Rimpiläinen
Tatu Rimpiläinen
ANAlexandra Nunes
Alexandra Nunes
RCRita Calado
Rita Calado
Ana FernandesAna Fernandes
Ana Fernandes
JAJoana Andrade
Joana Andrade
NCNuno Candeias
Nuno Candeias

10 March 2021 in ChemRxiv
Verified
Preprint
Open access
TRTatu Rimpilainen
Tatu Rimpilainen
ANAlexandra Nunes
Alexandra Nunes
RCRita Calado
Rita Calado
Ana FernandesAna Fernandes
Ana Fernandes
JAJoana Andrade
Joana Andrade
NCNuno Candeias
Nuno Candeias
The search for antibacterial agents for the combat of nosocomial infections is a timely problem, as antibiotic-resistant bacteria continue to thrive. The effect of indoline substituents on the antibacterial properties of aminoalkylphenols was studied, leading to the development of a library of compounds with minimum inhibitory concentrations (MICs) as low as 1.18 µM. Two novel aminoalkylphenols were identified as particularly promising, after MIC and minimum bactericidal concentrations (MBC) determination against a panel of reference strain Gram-positive bacteria, and further confirmed against 40 clinical isolates (Staphylococcus aureus, S. epidermidis, Enterococcus faecalis, E. faecium, and Listeria monocytogenes). The same two aminoalkylphenols displayed low toxicity against two in vivo models (Artemia salina brine shrimp and Saccharomyces cerevisiae). The in vitro cytotoxicity evaluation (on human keratinocytes and human embryonic lung fibroblast cell lines) of the same compounds was also carried out. They demonstrated a particularly toxic effect on the fibroblast cell lines, with IC50 in the 1.7-5.1 mM range, thus narrowing their clinical use. The desired increase in the antibacterial properties of the alkylaminophenols, particularly indoline-derived phenolic Mannich bases, was reached by introducing an additional nitro group in the indolinyl substituent or by the replacement of a methyl by a bioisosteric trifluoromethyl substituent. Notably, the introduction of an additional nitro moiety did not confer added toxicity to the alkylaminophenols.